Often, pharmaceutical companies avoid new laboratory testing methodologies preferring to stick to established procedures for drug development so as to avoid any potential regulatory ambiguity. This tendency to avoid new methodologies and regulatory scrutiny sometimes leads to slower progress, higher costs and lower probability of new product approvals. Furthermore, some pharmaceutical firms severely restrict academic research-based modifications to established laboratory testing procedures in drug development because of their concern over triggering costly adjustments to the established regulatory framework.
KFI is a veterinary contract research organization (CRO) that specializes in in-vivo GLP/GCP studies in dogs, cats and horses. We have a reputation for satisfying our clients by providing high quality services in a timely manner with the utmost attention to the latest scientific research and regulatory standards.
CPR Medical Devices, Inc. is a developer and manufacturer of patient-responsive emergency ventilation devices based on patented technology. These unique ventilatory devices are sold around the globe by independent distributors to EMS, hospitals, professionals and first responders. CPR's medical devices are marketed under the registered trade name Oxylator. They are simple, safe and effective, yet competitvely priced and are often teamed up with an AED (automatic external defibrillator) for most effective cardiopulmonary resuscitation.